Aaron Tachibana Sells 38,799 Shares of Personalis (NASDAQ:PSNL) Stock

Personalis, Inc. (NASDAQ:PSNL) CFO Aaron Tachibana sold 38,799 shares of the stock in a transaction that occurred on Friday, May 29th. The stock was sold at an average price of $11.58, for a total transaction of $449,292.42. Following the transaction, the chief financial officer owned 198,833 shares in the company, valued at approximately $2,302,486.14. The trade was a 16.33% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Personalis Stock Up 3.8%

Shares of NASDAQ:PSNL opened at $11.40 on Friday. The company’s 50 day moving average price is $6.86 and its two-hundred day moving average price is $8.10. Personalis, Inc. has a 12-month low of $3.84 and a 12-month high of $11.85. The firm has a market cap of $1.19 billion, a PE ratio of -11.18 and a beta of 1.96.

Personalis (NASDAQ:PSNL) last announced its earnings results on Thursday, May 7th. The company reported ($0.29) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.06). Personalis had a negative return on equity of 43.52% and a negative net margin of 148.11%.The business had revenue of $15.47 million for the quarter, compared to analyst estimates of $14.49 million. On average, research analysts expect that Personalis, Inc. will post -1.06 EPS for the current year.

Wall Street Analysts Forecast Growth

PSNL has been the topic of a number of analyst reports. Weiss Ratings restated a “sell (d-)” rating on shares of Personalis in a research report on Tuesday, April 21st. BTIG Research decreased their target price on shares of Personalis from $13.00 to $11.00 and set a “buy” rating on the stock in a research report on Monday, May 11th. Wall Street Zen upgraded shares of Personalis from a “sell” rating to a “hold” rating in a research report on Saturday. Morgan Stanley reduced their price target on shares of Personalis from $10.00 to $9.00 and set an “equal weight” rating on the stock in a research report on Tuesday, May 12th. Finally, Needham & Company LLC increased their price target on shares of Personalis from $10.00 to $12.00 and gave the stock a “buy” rating in a research report on Friday, February 27th. Five equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $11.00.

Institutional Trading of Personalis

Several large investors have recently made changes to their positions in the company. T. Rowe Price Investment Management Inc. boosted its position in shares of Personalis by 273.9% during the 4th quarter. T. Rowe Price Investment Management Inc. now owns 10,780,290 shares of the company’s stock worth $85,812,000 after acquiring an additional 7,896,714 shares in the last quarter. ARK Investment Management LLC boosted its position in shares of Personalis by 11.3% during the 3rd quarter. ARK Investment Management LLC now owns 7,910,191 shares of the company’s stock worth $51,574,000 after acquiring an additional 802,268 shares in the last quarter. Aberdeen Group plc boosted its position in shares of Personalis by 36.1% during the 4th quarter. Aberdeen Group plc now owns 3,249,895 shares of the company’s stock worth $25,869,000 after acquiring an additional 861,948 shares in the last quarter. Kennedy Capital Management LLC boosted its position in shares of Personalis by 196.2% during the 3rd quarter. Kennedy Capital Management LLC now owns 1,935,078 shares of the company’s stock worth $12,617,000 after acquiring an additional 1,281,695 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD boosted its position in shares of Personalis by 1,332.2% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 1,448,585 shares of the company’s stock worth $11,531,000 after acquiring an additional 1,347,439 shares in the last quarter. Institutional investors and hedge funds own 61.91% of the company’s stock.

About Personalis

Personalis, Inc (NASDAQ: PSNL) is a clinical‐stage genomics company that develops and markets advanced next‐generation sequencing (NGS) services and assays designed to accelerate precision medicine. The Company’s core offering is the ImmunoID NeXT™ Platform, which combines comprehensive tumor profiling—including whole exome, transcriptome, and T‐cell receptor sequencing—with proprietary bioinformatics to identify biomarkers and guide immuno‐oncology research. Personalis serves biopharmaceutical companies, academic institutions, and clinical research organizations seeking in‐depth insights into cancer, autoimmune diseases and other complex conditions.

In addition to its flagship ImmunoID NeXT™ Platform, Personalis offers a suite of customizable sequencing assays for biomarker discovery, clinical trial support and companion diagnostic development.